Clinical Trial Update: [18F]-DPA-714 PET/CT (Positron Emission Tomography/Computerized Tomography) in Triple Negative Breast Cancers [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating 18F-DPA-714 PET/CT in patients with triple negative breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• [18F]DPA-714 (DPA-714)

Snippet

Sponsor: Institut Cancerologie de l'Ouest | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: COMPLETED